Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability.

Neutrophil-dependent vascular injury gives rise to increased vascular permeability, edema, and further release of chemoattractants. Leukotriene B 4 (LTB 4 ) is among the most potent neutrophil stimuli and thus participates in tissue injury via recruiting neutrophils (PMNs, polymorphonuclear leukocytes) in pathophysiologic scenarios (1). Lipoxins are trihydroxytetraene-containing eicosanoids that are, among other in vivo sites, also generated within vascular lumen primarily by platelet-leukocyte interactions by pathways (Figure 1) that are activated during multicellular responses such as inflammation, atherosclerosis, and thrombosis (for a review, see Reference 2). In addition, aspirin has been found to trigger the transcellular biosynthesis of a new group of compounds termed 15-epi-lipoxins (15-epi-LXs) or aspirin-triggered lipoxins, which are likely to contribute to some of the beneficial actions ascribed to aspirin by serving as local endogenous antiinflammatory lipid mediators (2). Thus, these LX branches illustrated in Figure 1 involve cell-cell interactions that appear to produce endogenous stop signals or antiinflammatory compounds, while the 5-lipoxygenase pathway generates leukotrienes that evoke cellular events that are considered to be proinflammatory.

[1]  C. Clish,et al.  Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  C. Clish,et al.  Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  C. Clish,et al.  Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.

[4]  T. Takano,et al.  Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors , 1997, The Journal of experimental medicine.

[5]  G. Levy Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Serhan Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? , 1997, Prostaglandins.

[7]  C. Serhan,et al.  Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. , 1996, Journal of immunology.

[8]  E. Tagaya,et al.  Lipoxin A4 inhibits cholinergic neurotransmission through nitric oxide generation in the rabbit trachea. , 1995, European journal of pharmacology.

[9]  M. Savage,et al.  Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) , 1995, Circulation.

[10]  I. Akritopoulou‐Zanze,et al.  Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. , 1995, Biochemistry.

[11]  P. Ward,et al.  Mechanisms of neutrophil-dependent and neutrophil-independent endothelial cell injury. , 1994, Biological signals.

[12]  C. Serhan,et al.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. , 1993, The Journal of clinical investigation.

[13]  B. Spur,et al.  Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. , 1989, Clinical science.

[14]  B. Samuelsson From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences , 1983 .